RAPP

NASDAQ Healthcare

Rapport Therapeutics, Inc. - Common Stock

Biotechnology

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.

๐ŸŽฏ Investment Strategy Scores

RAPP scores across each investment strategy. Higher is better for that strategy's goals.

High dividend yield + low volatility
๐Ÿš€ Moon Shot 15/100โ€” 0
High growth potential (high beta + oversold)
๐Ÿ”ช Falling Knife 35/100โ–ผ -6
Contrarian plays (oversold + below moving average)
๐ŸŽˆ Over-Hyped 28/100โ–ฒ +7
Overbought stocks (potential short candidates)
Large-cap, institutional-quality stocks
๐Ÿ” Strategy Interpretation

Best fit: ๐Ÿ”ช Falling Knife (35/100) โ€” this strategy Contrarian plays (oversold + below moving average).

Lowest fit among scored strategies: ๐Ÿš€ Moon Shot (15/100). No single score is a buy or sell signal โ€” use multiple lenses together. Learn how to read these scores โ†’

Find RAPP in your text

Paste any article, transcript, or post โ€” the tool will extract RAPP and every other hidden ticker.

Try the Ticker Extractor โ†’

Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.